At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 469 enrolled
Drug / intervention
Progressive Addition Lenses +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Correction of Myopia Evaluation Trial (COMET)
In Brief
A Phase 3 clinical trial evaluating Progressive Addition Lenses and single vision lenses for Myopia. Completed, enrolled 469 participants across 4 sites.
Detailed Summary
To evaluate whether progressive addition lenses (PALs) slow the rate of progression of juvenile-onset myopia (nearsightedness) when compared with single vision lenses, as measured by cycloplegic autorefraction. An additional outcome measure is axial length, as measured by A-scan ultrasonography. To describe the natural history of juvenile-onset myopia in a group of children receiving conventional treatment (single vision lenses).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia
CountriesUnited States
CollaboratorsNational Eye Institute (NEI)
Timeline
Phase 3CompletedFinished
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 1997
First PostedSep 1999
Primary CompletionOct 2001
Study CompletionSep 2013
TodayJul 2026
First PostedSep 24, 1999
Enrollment StartSep 1, 1997
Primary CompletionOct 1, 2001
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 26.8 years ago
Interventions
Progressive Addition Lensesother
Varilux comfort with +2.00 addition
single vision lensesother